

Elisabet Zamora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/151900/publications.pdf>

Version: 2024-02-01

68
papers

2,362
citations

218381

26
h-index

223531

46
g-index

81
all docs

81
docs citations

81
times ranked

3330
citing authors

#	ARTICLE	IF	CITATIONS
1	Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2014, 63, 158-166.	1.2	222
2	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. <i>European Journal of Heart Failure</i> , 2017, 19, 1615-1623.	2.9	149
3	Soluble Nephrylin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2015, 65, 657-665.	1.2	137
4	Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 591-601.	1.2	132
5	Estimated Glomerular Filtration Rate and Prognosis in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1709-1715.	1.2	121
6	Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.1	97
7	Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. <i>International Journal of Cardiology</i> , 2015, 184, 337-343.	0.8	92
8	Soluble ST2 Serum Concentration and Renal Function in Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 768-775.	0.7	87
9	Advanced interatrial block predicts new-onset atrial fibrillation and ischemic stroke in patients with heart failure: The 'Bayes' Syndrome-HF study. <i>International Journal of Cardiology</i> , 2018, 271, 174-180.	0.8	71
10	Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. <i>European Journal of Heart Failure</i> , 2018, 20, 67-75.	2.9	63
11	Weight Loss in Obese Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, e002468.	1.6	59
12	Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment. <i>Mayo Clinic Proceedings</i> , 2013, 88, 234-243.	1.4	57
13	The obesity paradox in heart failure: Is etiology a key factor?. <i>International Journal of Cardiology</i> , 2013, 166, 601-605.	0.8	52
14	Renal function largely influences Galectin-3 prognostic value in heart failure. <i>International Journal of Cardiology</i> , 2014, 177, 171-177.	0.8	52
15	Impact of diabetes on the predictive value of heart failure biomarkers. <i>Cardiovascular Diabetology</i> , 2016, 15, 151.	2.7	51
16	No benefit from the obesity paradox for diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 851-858.	2.9	49
17	Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. <i>European Journal of Heart Failure</i> , 2019, 21, 1259-1266.	2.9	46
18	Fragility is a key determinant of survival in heart failure patients. <i>International Journal of Cardiology</i> , 2014, 175, 62-66.	0.8	45

#	ARTICLE	IF	CITATIONS
19	Prognostic Value and Kinetics of Soluble Natriuretic Peptide in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 641-644.	1.9	44
20	Body mass index, body fat, and nutritional status of patients with heart failure: The PLICA study. <i>Clinical Nutrition</i> , 2015, 34, 1233-1238.	2.3	42
21	Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification. <i>Clinica Chimica Acta</i> , 2013, 426, 18-24.	0.5	34
22	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. <i>International Journal of Cardiology</i> , 2018, 257, 188-192.	0.8	32
23	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 355-361.	0.7	31
24	Mini nutritional assessment is a better predictor of mortality than subjective global assessment in heart failure out-patients. <i>Clinical Nutrition</i> , 2019, 38, 2740-2746.	2.3	30
25	Long-term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C. <i>Clinical Chemistry</i> , 2014, 60, 481-489.	1.5	28
26	Head-to-head comparison of contemporary heart failure risk scores. <i>European Journal of Heart Failure</i> , 2021, 23, 2035-2044.	2.9	26
27	Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Natriuretic Peptide vs NT-proBNP. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1075-1084.	0.4	23
28	Effect of Fragility on Quality of Life in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 1785-1789.	0.7	22
29	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732092761.	0.8	21
30	Mini Nutritional Assessment Short Form is a morbi-mortality predictor in outpatients with heart failure and mid-range left ventricular ejection fraction. <i>Clinical Nutrition</i> , 2020, 39, 3395-3401.	2.3	21
31	Barcelona BioHF Calculator Version 2.0: incorporation of angiotensin II receptor blocker natriuretic peptide inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018, 20, 938-940.	2.9	20
32	Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 206.	0.7	18
33	Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 176-185.	1.2	18
34	Niveles sÃ©ricos de miostatina en insuficiencia cardiaca crÃ³nica. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 992-996.	0.6	17
35	A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. <i>International Journal of Cardiology</i> , 2019, 293, 148-152.	0.8	16
36	Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification. <i>PLoS ONE</i> , 2012, 7, e51234.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. <i>Scientific Reports</i> , 2021, 11, 732.	1.6	14
38	Cin�tica de la hemoglobina y pron�stico a largo plazo en insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 820-826.	0.6	13
39	Autoimmunity and Atrioventricular Block of Unknown Etiology in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1335-1336.	1.2	12
40	Aging and Heart Rate in Heart Failure: Clinical Implications for Long-term Mortality. <i>Mayo Clinic Proceedings</i> , 2015, 90, 765-772.	1.4	12
41	Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 37.	1.1	12
42	Wearable vest for pulmonary congestion tracking and prognosis in heart failure: A pilot study. <i>International Journal of Cardiology</i> , 2016, 215, 77-79.	0.8	12
43	First-in-man Safety and Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar. <i>EBioMedicine</i> , 2016, 7, 248-254.	2.7	12
44	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 924-932.	0.4	12
45	Serum Myostatin Levels in Chronic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 992-996.	0.4	11
46	Estimated creatinine clearance: a determinant prognostic factor in heart failure. <i>Medicina Cl�nica</i> , 2008, 131, 47-51.	0.3	10
47	Obesidad y pron�stico a largo plazo en la insuficiencia cardiaca: la paradoja contin�a. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 1210-1212.	0.6	10
48	The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. <i>Biomarkers</i> , 2016, 21, 225-232.	0.9	9
49	Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. <i>Cardiovascular Diabetology</i> , 2020, 19, 38.	2.7	9
50	Circulating monocyte subsets and heart failure prognosis. <i>PLoS ONE</i> , 2018, 13, e0204074.	1.1	8
51	Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 820-826.	0.4	7
52	Palliative Care Needs in Heart Failure. A Multicenter Study Using the NECPAL Questionnaire. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 870-872.	0.4	6
53	Prognostic value of lung ultrasound in chronic stable ambulatory heart failure patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 862-869.	0.4	4
54	Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality. <i>Journal of Clinical Medicine</i> , 2022, 11, 784.	1.0	4

#	ARTICLE	IF	CITATIONS
55	Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure: Association with Prognosis. <i>Nutrients</i> , 2022, 14, 2244.	1.7	4
56	Obesity and Long-Term Prognosis in Heart Failure: the Paradox Persists. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 1210-1211.	0.4	3
57	Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 836451.	1.1	3
58	Myostatin serum levels in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1379-1379.	2.9	2
59	Impact of a "stent for life"™ initiative on post-ST elevation myocardial infarction heart failure: a 15-year heart failure clinic experience. <i>ESC Heart Failure</i> , 2018, 5, 101-105.	1.4	2
60	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 20.	0.8	2
61	Limitación al flujo arterial en pacientes con insuficiencia cardíaca: prevalencia y factores asociados. <i>Medicina Clínica</i> , 2019, 153, 191-195.	0.3	1
62	Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?. <i>PLoS ONE</i> , 2021, 16, e0249674.	1.1	1
63	Seudorreestenosis de stent por anillo de calcio. <i>Revista Espanola De Cardiologia</i> , 2007, 60, 883-884.	0.6	0
64	Respuesta. <i>Revista Espanola De Cardiologia</i> , 2008, 61, 217-218.	0.6	0
65	Osteosarcoma in left atrium treated with autotransplant. <i>European Heart Journal</i> , 2008, 29, 2446-2446.	1.0	0
66	Reply. <i>European Journal of Heart Failure</i> , 2017, 19, 1736-1736.	2.9	0
67	Airflow limitation in patients with heart failure: Prevalence and associated factors. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 191-195.	0.1	0
68	Myocardial Ischemia Amelioration Reducing Venous Outflow. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 1077.	0.4	0